Why the study?
The potential role of adjunctive colchicine after bare-metal stent implantation compared with drug-eluting stent alone was unknown.
Does bare-metal stent implantation plus 1 mg of colchicine during 3 months improve cost-effectiveness at 1 year compared to drug-eluting stent alone in patients undergoing percutaneous coronary intervention?
Does bare-metal stent implantation plus 1 mg of colchicine during 3 months improve cost-effectiveness at 1 year compared to drug-eluting stent alone in patients undergoing percutaneous coronary intervention?
This study protocol aims to evaluate the cost-effectiveness of bare-metal stenting combined with 3 months of colchicine versus drug-eluting stenting alone.
Answers are grounded in this paper and cite their sources.
Colchicine reduces cardiac events in CAD; extends prior anti-inflammatory findings to adjunctive use after bare-metal stenting.
The use of colchicine is associated with a significant reduction of cardiac adverse events in patients with coronary artery disease. Past small randomized trials with oral immunosuppressive or anti-inflammatory therapies have demonstrated a reduction of adverse clinical events after bare metal stent implantation. The potential role of adjunctive colchicine after bare-metal stent implantation, compared with drug-eluting stent alone, is unknown. The primary end point of the study will be to compare cost-effectiveness at 1 year of follow-up of coronary intervention with bare-metal stent implantation plus 1 mg of colchicine during 3 months versus percutaneous coronary intervention with drug-eluting stent implantation alone. ClinicalTrials.gov identifier: NCT04382443.
No takes yet. Share an insight, caveat, or question.
Correa-Sadouet et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: